---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-026642"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:51:40.276472+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Vanda Pharmaceuticals appoints Dr. Charles Duncan to Board of Directors effective April 22, 2026

## Summary
- Board expands from six to seven members; Duncan appointed as Class II director with term ending at 2026 annual meeting.
- Initial RSU award of $390,000 vests quarterly over four years; annual cash retainer of $50,000.
- Additional annual RSU award of $260,000 after each annual meeting starting 2026, vesting one year later.
- Duncan previously Managing Director at Cantor Fitzgerald, covering >70 biotech companies; founded Sulci Advisors in Sep 2025.
- Duncan cites recent approvals of NEREUS and BYSANTI, label expansion for Fanapt, and pipeline catalysts over next 12 months.

## SEC filing metadata
- accession: 0001628280-26-026642
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/0001628280-26-026642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/vnda-20260422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-026642
- JSON: https://secwatch.observer/filing/0001628280-26-026642.json
- Plain text: https://secwatch.observer/filing/0001628280-26-026642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.